Chantal LAGRESLE

Trials

Studies that name Chantal LAGRESLE as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:28 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT06736080 · Safety and Efficacy of Gene Therapy of FHL Type 3 Caused by Mutations in the Human UNC13D Gene by Transplantation of a Single Dose of Autologous CD34+ Cells Transduced ex Vivo With the UNC13D LV Vector Expressing the UNC13D cDNA

  Assistance Publique - Hôpitaux de Paris · not yet recruiting · Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3) · study director
• Ph1/Ph2
  NCT05071222 · Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)

  Assistance Publique - Hôpitaux de Paris · recruiting · Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 06:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.